Экспериментальая оценка дополнительной гормональной активности прегнанового гестагена гестобутаноила

The ability of a pregnane steroid with progestogen activity gestobutanoyl to have additive glucocorticoid, mineralocorticoid, antiadrogenic, estrogenic effects in rats have been studied. It was found that gestobutanoyl did not have estrogenic activity, as it did not increase the weight of the uterus with prolonged (30 days) administration both at a therapeutic dose of 0.25 mg/kg and at a dose 10 and 100 times higher concentrations. Gestobutanoyl did not show glucocorticoid activity: at 30 days of administration of gestobutanoyl at a dose of 2.5 mg/kg the mass of the thymus did not change. However, when administered at a high dose, 100 times higher than therapeutic – 25 mg/kg, the mass of the thymus decreased by 25% ( p ≤ 0.05). Gestobutanoyl at a dose of 2.5 mg/kg reduced the expression of androgen receptor mRNA in the uterus of rats by more than 3 times and, as it was previously shown, did not increase the weight of the prostate and muscle m.levator ani. In a study of the mineralocorticoid activity of gestobutanoyl tablets, when administered orally to female rats in doses exceeding the therapeutic 100 and 1000 times (2.5 and 25 mg/kg, respectively) for 14 days there was no decrease in diuresis in all experimental groups, no there was water retention in the body of rats, electrolytes were excreted in the urine and were present in the urine in constant concentrations, indicating the absence of side mineralocorticoid effects of gestobutanoyl tablets.